Cytosolic phospholipase A2α contributes to blood pressure increases and endothelial dysfunction under chronic no inhibition

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 31, Issue 5, 2011, Pages 1133-1138

  Tanaka, Kohei ^a   Yamamoto, Yasutaka ^a   Ogino, Kazuhide ^b   Tsujimoto, Shunsuke ^a   Saito, Motoaki ^c   Uozumi, Naonori ^d   Shimizu, Takao ^d   Hisatome, Ichiro ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b TOTTORI UNIVERSITY HOSPITAL   (Japan)

^c TOTTORI UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

Endothelium; hypertension; L NAME; nitric oxide; phospholipase A2

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ARACHIDONIC ACID; CYTOSOLIC PHOSPHOLIPASE A2ALPHA; LEUKOTRIENE B4; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PHOSPHOLIPASE A2; RENIN; THROMBOXANE B2; UNCLASSIFIED DRUG; ENZYME INHIBITOR; ICOSANOID; NITRIC OXIDE SYNTHASE; PHOSPHOLIPASE A2 GROUP IV; PLA2G4A PROTEIN, MOUSE; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; ARACHIDONIC ACID METABOLISM; ARTERY ENDOTHELIUM; ARTERY MUSCLE; ARTICLE; BLOOD CELL; BLOOD PRESSURE REGULATION; BONE MARROW TRANSPLANTATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOSOL; DIASTOLIC BLOOD PRESSURE; ENDOTHELIAL DYSFUNCTION; FATTY ACID BLOOD LEVEL; GENE DELETION; HEART; HYPERTENSION; KIDNEY; MOUSE; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; SYSTOLIC BLOOD PRESSURE; VASCULAR RING; WILD TYPE; ANIMAL; BLOOD; BLOOD PRESSURE; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETICS; MALE; METABOLISM; MOUSE MUTANT; PATHOPHYSIOLOGY; PHOSPHORYLATION; THORACIC AORTA; TIME; TISSUE CULTURE TECHNIQUE; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; VASODILATATION;

ANIMALS; AORTA, THORACIC; BLOOD PRESSURE; BONE MARROW TRANSPLANTATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EICOSANOIDS; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; GROUP IV PHOSPHOLIPASES A2; HYPERTENSION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHOSPHORYLATION; RENIN; TIME FACTORS; TISSUE CULTURE TECHNIQUES; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATION; VASODILATOR AGENTS;

EID: 79955620735     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.218370     Document Type: Article

References (44)

1. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, Fishman MC. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature. 1995;377:239-242.
2. Shesely EG, Maeda N, Kim HS, Desai KM, Krege JH, Laubach VE, Sherman PA, Sessa WC, Smithies O. Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc Natl Acad Sci USA. 1996;93:13176-13181. (Pubitemid 26382789)
3. Node K, Kitakaze M, Yoshikawa H, Kosaka H, Hori M. Reduced plasma concentrations of nitrogen oxide in individuals with essential hypertension. Hypertension. 1997;30:405-408. (Pubitemid 27446100)
4. Panza JA, Quyyumi AA, Brush JE, Epstein SE. Abnormal endotheliumdependent vascular relaxation in patients with essential hypertension. N Eng J Med. 1990;323:22-27. (Pubitemid 20209468)
5. Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A, Ferraro A, Chello M, Mastroroberto P, Verdecchia P, Schillaci G. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation. 2001;104:191-196. (Pubitemid 32655837)
6. Lloyd-Jones DM, Bloch KD. The vascular biology of nitric oxide and its role in atherogenesis. Annu Rev Med. 1996;47:365-375. (Pubitemid 26138897)
7. Knowles JW, Reddick RL, Jennette JC, Shesely EG, Smithies O, Maeda N. Enhanced atherosclerosis and kidney dysfunction in eNOS(/) ApoE(/) mice are ameliorated by enalapril treatment. J Clin Invest. 2000;105:451-458. (Pubitemid 30127245)
8. Kuhlencordt PJ, Gyurko R, Han F, Scherrer-Crosbie M, Aretz TH, Hajjar R, Picard MH, Huang PL. Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice. Circulation. 2001;104: 448-454. (Pubitemid 32678276)
9. Feng Q, Song W, Lu X, Hamilton JA, Lei M, Peng T, Yee SP. Development of heart failure and congenital septal defects in mice lacking endothelial nitric oxide synthase. Circulation. 2002;106:873-879.
10. Fraccarollo D, Widder JD, Galuppo P, Thum T, Tsikas D, Hoffmann M, Ruetten H, Ertl G, Bauersachs J. Improvement in left ventricular after experimental myocardial infarction. Circulation. 2008;118:818-827.
11. Hegen M, Sun L, Uozumi N, Kume K, Goad ME, Nickerson-Nutter CL, Shimizu T, Clark JD. Cytosolic phospholipase A2-deficient mice are resistant to collagen-induced arthritis. J Exp Med. 2003;197:1297-1302. (Pubitemid 36617776)
12. Chen M, Boilard E, Nigrovic PA, Clark P, D Xu, Fitzgerald GA, Audoly LP, Lee DM. Predominance of cyclooxygenase 1 over cyclooxygenase 2 in the generation of proinflammatory prostaglandins in autoantibodydriven K/BxN serum-transfer arthritis. Arthritis Rheum. 2008;58: 1354-1365. (Pubitemid 351705925)
13. Caterina DR, Zampolli A. From asthma to atherosclerosis-5-lipoxygenase, leukotrienes, and inflammation. N Engl J Med. 2004;350:4-7.
14. Nagase T, Uozumi N, Ishii S, Kume K, Izumi T, Ouchi Y, Shimizu T. Acute lung injury by sepsis and acid aspiration: a key role for cytosolic phospholipase A2. Nat Immunol. 2000;1:42-46.
15. Uozumi N, Kume K, Nagase T, Nakatani N, Ishii S, Tashiro F, Komagata Y, Maki K, Ikuta K, Ouchi Y, Miyazaki J, Shimizu T. Role of cytosolic phospholipase A2 in allergic response and parturition. Nature. 1997;390: 618-622. (Pubitemid 28016197)
16. Burleigh ME, Babaev VR, Oates JA, Harris RC, Gautam S, Riendeau D, Marnett LJ, Morrow JD, Fazio S, Linton MF. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation. 2002;105:1816-1823. (Pubitemid 34408892)
17. Mehrabian M, Allayee H, Wong J, Shi W, Wang XP, Shaposhnik Z, Funk CD, Lusis AJ. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res. 2002;91: 120-126. (Pubitemid 34827222)
18. Egan KM, Wang M, Fries S, Lucitt MB, Zukas AM, Puré E, Lawson JA, FitzGerald GA. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation. 2005;111:334-342. (Pubitemid 40165341)
19. Babaev VR, Ding L, Reese J, Morrow JD, Breyer MD, Dey SK, Fazio S, Linton MF. Cyclooxygenase-1 deficiency in bone marrow cells increases early atherosclerosis in apolipoprotein E-and low-density lipoprotein receptor-null mice. Circulation. 2006;113:108-117. (Pubitemid 43958495)
20. Tomida T, Numaguchi Y, Nishimoto Y, Tsuzuki M, Hayashi Y, Imai H, Matsui H, Okumura K. Inhibition of COX-2 prevents hypertension and proteinuria associated with a decrease of 8-iso-PGF2 formation in L-NAME-treated rats. J Hypertens. 2003;21:601-609. (Pubitemid 36418973)
21. Stanke-Labesque F, Hardy G, Caron F, Cracowski JL, Bessard G. Inhibition of leukotriene synthesis with MK-886 prevents a rise in blood pressure and reduces noradrenaline-evoked contraction in L-NAMEtreated rats. Br J Pharmacol. 2003;140:186-194. (Pubitemid 37175844)
22. Bonventre JV, Huang Z, Taheri MR, O'Leary E, Li E, Moskowitz MA, Sapirstein A. Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A2. Nature. 1997;390:622-625. (Pubitemid 28016198)
23. Nagase T, Uozumi N, Ishii S, Kita Y, Yamamoto H, Ohga E, Ouchi Y, Shimizu T. A pivotal role of cytosolic phospholipase A2 in bleomycininduced pulmonary fibrosis. Nature Med. 2002;8:480-484. (Pubitemid 34546750)
24. Ichinose F, Ullrich R, Sapirstein A, Jones RC, Bonventre JV, Serhan CN, Bloch KD, Zapol WM. Cytosolic phospholipase A(2) in hypoxic pulmonary vasoconstriction. J Clin Invest. 2002;109:1493-1500. (Pubitemid 34596175)
25. Haq S, Kilter H, Michael A, Tao J, O'Leary E, Sun XM, Walters B, Bhattacharya K, Chen X, Cui L, Andreucci M, Rosenzweig A, Guerrero JL, Patten R, Liao R, Molkentin J, Picard M, Bonventre JV, Force T. Deletion of cytosolic phospholipase A2 promotes striated muscle growth. Nat Med. 2003;9:944-951. (Pubitemid 36889939)
26. Takemoto M, Egashira K, Usui M, Numaguchi K, Tomita H, Tsutsui H, Shimokawa H, Sueishi K, Takeshita A. Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. J Clin Invest. 1997;99:278-287. (Pubitemid 27053468)
27. Tomita H, Egashira K, Kubo-Inoue M, Usui M, Koyanagi M, Shimokawa H, Takeya M, Yoshimura T, Takeshita A. Inhibition of NO synthesis induces inflammatory changes and monocyte chemoattractant protein-1 expression in rat hearts and vessels. Arterioscler Thromb Vasc Biol. 1998;18:1456-1464. (Pubitemid 28421884)
28. Numaguchi K, Egashira K, akemoto M, Kadokami T, Shimokawa H, Sueishi K, Takeshita A. Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. Hypertension. 1995; 26:957-962.
29. Harizi H, Corcuff JB, Gualde N. Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology. Trends Mol Med. 2008;14: 461-469.
30. Back M, Sakata K, Qiu H, Haeggström JZ, Dahlen SE. Endotheliumdependent vascular responses induced by leukotriene B4. Prostaglandins Other Lipid Mediat. 2007;83:209-212. (Pubitemid 46661260)
31. Stanke-Labesque F, Devillier P, Veitl S, Caron F, Cracowski JL, Bessard G. Cysteinyl leukotrienes are involved in angiotensin II-induced contraction of aorta from spontaneously hypertensive rats. Cardiovasc Res. 2001;49:152-160.
32. Pfister SL, Pratt PE, Kurian J, Campbell WB. Glibenclamide inhibits thromboxane-mediated vasoconstriction by thromboxane receptor blockade. Vascul Pharmacol. 2004;40:285-292. (Pubitemid 38452713)
33. Guan Y, Zhang Y, Wu J, Qi Z, Yang G, Dou D, Gao Y, Chen L, Zhang X, Davis LS, Wei M, Fan X, Carmosino M, Hao C, Imig JD, Breyer RM, Breyer MD. Antihypertensive effects of selective prostaglandin E2 receptor subtype 1 targeting. J Clin Invest. 2007;117:2496-2505. (Pubitemid 47494351)
34. Francois H, Makhanova N, Ruiz P, Ellison J, Mao L, Rockman HA, Coffman TM. A role for the thromboxane (TP) receptor in L-NAME hypertension. Am J Physiol Renal Physiol. 2008;295:1096-1102.
35. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286:954-959. (Pubitemid 33010342)
36. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med. 2004; 351:1709-1711.
37. Huo Y, Zhao L, Hyman MC, Shashkin P, Harry BL, Burcin T, Forlow SB, Stark MA, Smith DF, Clarke S, Srinivasan S, Hedrick CC, Praticò D, Witztum JL, Nadler JL, Funk CD, Ley K. Critical role of macrophage 12/15-lipoxygenase for atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2004;110:2024-2031. (Pubitemid 39331917)
38. Zhou Y, Varadharaj S, Zhao X, Parinandi N, Flavahan NA, Zweier JL. Acetylcholine causes endothelium-dependent contraction of mouse arteries. Am J Physiol Heart Circ Physiol. 2005;289:1027-1032.
39. Granström E, Kindahl H, Samuelsson B. A method for measuring the unstable thromboxane A2: radioimmunoassay of the derived mono O-methyl thromboxane B2. Prostaglandins. 1976;12:929-941. (Pubitemid 8015245)
40. Keppler D, Huber M, Baumert T, Guhlmann A. Metabolic inactivation of leukotrienes. Adv Enzyme Regul. 1989;28:307-319.
41. Wong MS, Vanhoutte PM. COX-mediated endothelium dependent contractions: from the past to recent discoveries. Acta Pharmacol Sin. 2010; 31:1095-1102.
42. Boekholdt SM, Keller TT, Wareham NJ, Luben R, Bingham SA, Day NE, Sandhu MS, Jukema JW, Kastelein JJ, Hack CE, Khaw KT. Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. Arterioscler Thromb Vasc Biol. 2005;25: 839-846. (Pubitemid 40463879)
43. Qi Z, Hao CM, Langenbach RI, Breyer RM, Redha R, Morrow JD, Breyer MD. Opposite effects of cyclooxygenase-1 and-2 activity on the pressor response to angiotensin II. J Clin Invest. 2002;110:61-69. (Pubitemid 34743466)
44. Francois H, Coffman TM. Prostanoids and blood pressure: which way is up? J Clin Invest. 2004;114:757-759. (Pubitemid 39578732)